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Dissociation of mesangial cell migration and proliferation in nephropathy, membranoproliferative glomerulonephri-
experimental glomerulonephritis. tis, diabetic nephropathy, and allograft rejection [1]. We
Background. Recently, we documented that following in have gained insight into the repair process followingvivo mesangial cell (MC) ablation in the Thy1 model, reconsti-
mesangiolytic injury by using an animal model of experi-tution of the mesangium occurs by a coordinated proliferation
mental mesangioproliferative nephritis (Thy1) [2]. In theand migration of Thy1 (OX-7)-positive cells originating from
the hilus and extraglomerular mesangium. We investigated the Thy1 model, injury to the mesangium is followed by a
role of basic fibroblast growth factor (bFGF) in the mediation reproducible recovery process characterized by matrix
of these events. remodeling [3], capillary angiogenesis [4], and the resto-Methods. Rats were injected with antithymocyte serum and
ration of normal glomerular cellularity by a balance of48 hours later were pulsed with 3H-thymidine to label prolifer-
proliferation and apoptosis [5, 6]. Recently, we haveating cells. Ninety minutes later, a baseline renal biopsy was
obtained, and rats were injected with neutralizing anti-bFGF characterized an additional process crucial to mesangial
antibodies or control IgG. Sacrificial biopsies were obtained remodeling following injury: cell migration [7]. The abil-
at 96 hours of disease. Using computer image analysis, biopsies ity of mesangial cells (MCs) to migrate in vivo was origi-from both time points were quantitated for the number of
nally suggested by the observations of Barnes et al, whoradiolabeled MC (proliferation) and their mean distance from
showed that glomerular microaneurysm repair in thethe hilus (migration). The effect of bFGF on the migration of
MCs in culture was examined using a chemotactic assay. Habu snake venom model is characterized by the appear-
Results. At sacrifice, autoradiographs of rats receiving anti- ance of desmin-positive MCs initially at the aneurysm
bFGF had significantly fewer radiolabeled MCs as compared
peripheries and later within aneurysms [8]. Subse-with rats receiving control IgG (8.7 6 1.9 vs. 14.7 6 3.5, P 5
quently, using tritiated thymidine labeling in combina-0.0001), yielding an overall 40% reduction in proliferation.
There was no difference, however, in the final distance of tion with serial renal biopsies, we have shown that follow-
radiolabeled MCs from the glomerular hilus in the two groups, ing MC ablation in the Thy1 model, reconstitution of
indicating that the administration of anti-bFGF did not effect the mesangium occurs by a coordinated migration andMC migration in this model. In an in vitro chemotactic assay,
proliferation of Thy1-positive cells originating in the hi-MCs migrated in response to platelet-derived growth factor
lus and extraglomerular mesangium [7]. These mesangial(PDGF) BB (20 ng/ml), but did not migrate in response to
bFGF at a wide range of concentrations (0.5 to 50 ng/ml). “progenitor” cells stain negatively for renin, macro-
Conclusions. These studies demonstrate that bFGF is an phage, and smooth muscle markers and thus represent
important mediator of MC proliferation but that it does not
reserve cells that serve to repopulate the mesangiumsignificantly influence MC migration. This is the first demon-
following injury.stration showing that the mediators effecting proliferation can
be dissociated from those mediating migration in renal injury. In contrast to the well-characterized mediators of MC
proliferation in vivo [9, 10], the cytokines modulating
MC migration in vivo have not been defined. It is possible
Severe disruption of the mesangium, “mesangiolysis,” that the growth factors mediating proliferation may also
is a feature of many human renal diseases, including IgA mediate migration. Alternatively, distinct growth factors
may regulate these separate cellular events. One poten-
tial candidate is basic fibroblast growth factor (bFGF),Key words: basic fibroblast growth factor, renal injury, mesangiolysis,
membranoproliferative glomerulonephritis, Thy1 model, apoptosis. an 18 kDa cationic polypeptide capable of exerting nu-
merous biological effects [11]. bFGF is both mitogenicReceived for publication November 25, 1998
and chemotactic for a variety of cell types and is known toand in revised form March 23, 1999
Accepted for publication April 12, 1999 play an important role in wound healing, embryogenesis,
and angiogenesis [11]. In the kidney, bFGF is a potent 1999 by the International Society of Nephrology
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MC mitogen in vitro [12] and is constitutively expressed in vitro migration assay was performed using Transwell
tissue culture plates (Corning-Costar, Bedford, MA,by rat MCs (RMCs) in vivo [13]. Following mesangiolytic
USA) embedded with a polycarbonate membrane (poreinjury in the Thy1 model, bFGF is thought to be released
size 12 mm). The chemoattractant of interest (1.5 ml offrom intracellular stores and is absent from the glomeru-
PDGF 20 ng/ml or bFGF at 0.5, 1.0, 10, 50 ng/ml) waslus at 24 hours following injury [13]. In contrast, a marked
pipetted into the bottom chamber of each well. Eachincrease in mesangial expression of bFGF can be demon-
plate included both positive (15% FCS) and negativestrated during the proliferative phase of disease (days 6
(serum-free medium) controls. MCs (1 3 105) in SFMto 14). It is thought that the mesangial release of bFGF
containing 1% BSA were placed in the top chambers,may stimulate proliferation in an autocrine fashion [13]
and the apparatus was incubated for six hours at 378C.or by up-regulating the release of other growth factors,
Following incubation, residual cells were removed fromsuch as platelet-derived growth factor (PDGF) [12].
the top of each membrane using cotton-tipped applica-bFGF is also an important chemoattractant and is known
tors alternating with phosphate-buffered saline washesto induce migration of a variety of cell types in culture,
(32). Cells that had migrated through the pores wereincluding endothelial cells, fibroblasts, and glia [11]. In
fixed to the underside of each membrane with methanolvivo, bFGF mediates migration of smooth muscle cells
(8 min). After drying, the membranes was stained with
(SMCs) from media to intima following balloon-medi- hematoxylin (Harleco, Gibbstown, NJ, USA), agitated
ated injury to the carotid artery [14]. manually in tap water, and submerged in ammonia water.
The growth factors mediating MC migration in vivo Individual membranes were cut out of each well and
have not been defined. Accordingly, we explored the mounted on large cover slips. Using a light microscope
role of bFGF in MC migration both in vitro and in vivo. at 3200 magnification, the number of cells in 10 sequen-
Our results demonstrate that bFGF is not a significant tial 1 mm2 fields were counted. All experiments were
MC chemoattractant in vitro. Furthermore, in the Thy1 run in triplicate (3) or duplicate (1). Results are reported
model of mesangioproliferative nephritis, bFGF is an as the mean cells/mm2 for the compilation of four experi-
important mediator of MC proliferation but does not ments.
appear to be required for effective MC migration. These
Experimental designstudies demonstrate that the mediators effecting prolif-
eration can be dissociated from those that mediate migra- Male Wistar Rats (Simonsen Laboratories, Gilroy,
tion in renal injury. CA, USA) weighing 170 to 220 g were used for all studies.
Experimental mesangioproliferative nephritis was in-
duced by tail vein bolus of goat anti-rat thymocyte
METHODS plasma (ATS) as previously described [2] The protocol
Reagents describing our in vivo migration assay has been described
in detail [7]. For this study, preliminary dose responseRecombinant human bFGF (rhbFGF) was obtained
studies (N 5 2 per group) were performed to determinecommercially (Collaborative Biomedical Products, Bed-
the optimal dose of ATS (range 0.4 to 1.0 ml/100 g) suchford, MA, USA). Affinity-purified polyclonal goat anti-
that an injection of tritiated thymidine at 48 hours wouldrhbFGF was prepared and purified as previously de-
label approximately 2 to 6 3[H]-thymidine 1/Thy1 1scribed [15]. In mitogenicity assays using NIH 3T3 cells,
MCs per glomerulus. The fate of these radiolabeled cellsthe antibody inhibited the mitogenic response to bFGF
could then be assessed with serial biopsies [7]. A dosein a concentration-dependent fashion but did not influ-
of 0.6 ml/100 g ATS was found to be optimal. In the firstence proliferation in response to a panel of other growth
protocol, male Wistar rats (N 5 6) were injected withfactors (PDGF, epidermal growth factor, acidic FGF)
ATS (0.6 ml/100 g) on day 0. At 48 hours, all rats received[15]. Recombinant human PDGF BB was a generous
tail vein bolus injections of 3[H]-thymidine (120 mCi/100 ggift of Dr. Ronald A. Seifert (University of Washington
body wt; New England Nuclear, Boston, MA, USA).
Medical Center, Seattle, WA, USA). After 90 minutes, a baseline renal survival biopsy was
performed. Immediately following the biopsy, rats wereExperiments with cultured mesangial cells
injected intravenously with 60 mg of neutralizing anti-
Rat mesangial cells were prepared from collagenase- bFGF antibodies (N 5 3) or normal goat IgG (N 5 3).
digested glomeruli as previously described [16]. Cells of Injection of neutralizing antibody or control was re-
passages 17 to 23 were used for the in vitro migration peated at 72 hours. At 96 hours, rats were sacrificed
experiments. RMCs were grown to confluency in media and kidneys were harvested. The second protocol was
containing 15% fetal calf serum (FCS; Summit Biotech- identical, except that serial sacrificial biopsies, rather
nology, Ft. Collins, CO, USA), trypsinized, and resus- than survival biopsies, were obtained. Following the ini-
pended in serum-free media (SFM) containing 1% bo- tial 3[H]-thymidine injection (N 5 10), four rats were
sacrificed to obtain baseline renal biopsies. The re-vine serum albumin (BSA) as a carrier protein. The
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maining rats were injected with anti-bFGF (N 5 3) or
normal goat IgG (N 5 4) at 48 and 72 hours as described
earlier here; sacrificial biopsies were obtained at 96
hours. Data for the two studies were similar and there-
fore combined.
Immunohistochenistry and autoradiography
Renal biopsies were fixed in methyl Carnoy’s solution
and embedded in paraffin. Four micrometer sections
were stained with the murine IgG1 monoclonal antibody
OX-7 (Serotec Ltd., Oxford, UK), which detects the
Thy1 antigen, at 1:100,000, followed by a biotinylated
antimouse IgG1 (Zymed Laboratories, San Francisco,
CA, USA) at 1:400, horseradish peroxidase-conjugated
avidin D (Vector Laboratories, Inc., Burlingame, CA,
USA) at 1:2000, and diaminobenzidine (Sigma Chemical
Co., St. Louis, MO, USA). Controls consisted of omis-
sion of the primary antibody or substitution of the pri-
mary antibody with an irrelevant murine IgG of the same
Fig. 1. Measurement of in vivo migration. Proliferating mesangial cellssubclass. After staining, slides were dehydrated in graded
were identified by the presence of tritium (black nuclear grains) andalcohols, air dried overnight, dipped in NTB 2 emulsion
by positive staining for the rat mesangial cell (MC) surface antigen
(Kodak, Rochester, NY, USA), and placed in light tight Thy1 (clone OX-7, dark gray). This population of 3[H]-thymidine 1/
boxes. Following a three-week incubation at 48C, slides Thy1 1 cells was individually marked and connected to the hilar origin
using graphic tools. The mean distance of radiolabeled MCs from thewere developed (D19; Kodak) and counterstained with
hilus in a given glomerulus was then extracted from digitized imagesmethyl green (Sigma). (N 5 20 per biopsy).
Morphometric analysis of proliferation and migration
Measurements of cell migration and cell number were
made using the Optimas computer image analysis system
(Media Cybernetics, Silver Springs, MD, USA). Only
glomeruli in which the hilar area was clearly visible (N 5
20 to 25 per biopsy) were analyzed. Cells labeled with
3[H]-thymidine ($3 nuclear grains) and staining positive
for the RMC surface antigen Thy1 (OX-7) were marked,
and a line was drawn from each cell to the hilar origin
(Fig. 1). The outline of each glomerulus was traced using
a freehand area tool. Both the mean distance of 3[H]-
thymidine 1/Thy1 1 cells from the hilus and the distance
corrected for glomerular diameter were then extracted
from digitized images. The migratory rate was calculated
by dividing the distance traveled by radiolabeled MCs
by the time period studied. A minimum of 20 glomeruli Fig. 2. In vitro migration assay. Mesangial cells (MCs) migrated in
were measured in each biopsy. response to PDGF 20 ng/ml (*P , 0.0001 compared with serum-free
media), but did not migrate significantly in response to basic fibroblast
Statistical analysis growth factor (bFGF) at a range of concentrations. This histogram
reflects a compilation of data from four individual migration experi-Statistical results are expressed as mean 6 sd unless ments.
otherwise stated. Statistical significance, defined as P ,
0.05, was evaluated using one-way analysis of variance
with modified t-test performed with the Bonferroni cor-
rection. a potent chemotactic response. The number of cells mi-
grating through the membrane in contact with PDGF
RESULTS was 15-fold higher than the background (26.8 6 12.6 vs.
Mesangial cells in vitro migrate in response to PDGF 1.9 6 0.8, P , 0.0001). In contrast, bFGF tested at a range
but not bFGF of concentrations (0.5 to 50 ng/ml) did not stimulate
significant migration when compared to the backgroundThe results obtained from the in vitro migration assay
are summarized in Figure 2. PDGF (20 ng/ml) elicited (P 5 NS for all concentrations).
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Fig. 3. The Thy1 model at 48 (A) and 96 (B) hours. Representative periodic acid-Schiff–stained glomeruli exhibiting typical features of the Thy1
model. (A) Glomerulus exhibiting extensive foci of mesangiolysis. (B) Glomerulus exhibiting a dramatic, lobular, mesangioproliferative lesion
(3630).
Antibodies to bFGF inhibit mesangial cell 14.7 6 3.5, P 5 0.0001). Therefore, MCs of rats receiving
proliferation following injury in the Thy-1 model control IgG completed almost two cell divisions during
the two-day period, whereas MCs of rats receiving anti-The Thy1 model is characterized by an initial comple-
bFGF antibodies divided only once.ment-dependent mesangiolytic injury (day 1 to 2), associ-
ated with a platelet and mononuclear cell infiltrate. This
Antibodies to bFGF do not inhibit mesangial cellis followed by a period of intense MC proliferation (days
migration in the Thy1 model2 to 7) accompanied by matrix expansion and a pheno-
Computer image analysis was used to measure thetypic change of the MC to that of a “myofibroblast” [9, 17].
mean distance of 3[H] thymidine 1/Thy1 1 cells fromForty-eight hours following injection with ATS, rats
the glomerular hilus at 48 and 96 hours of disease (Figs. 1were injected with 3[H]-thymidine (120 mCi/100 g). Base-
and 4 A–D). At 48 hours, radiolabeled MCs were locatedline biopsies obtained 90 minutes after labeling revealed
at a mean distance of 49.2 6 4.1 mm from the hilus (Fig.extensive mesangiolysis in the vast majority of glomeruli
4 A, B). Analysis of 96-hour biopsies (Fig. 4 C, D) found(Fig. 3A), with scattered foci of microaneurysm formation.
radiolabeled MCs now localized at a mean distance ofInitial autoradiographs (Fig. 4 A, B) revealed small num-
71.4 6 5.6 mm from the hilus (P , 0.001 comparedbers of 3[H] thymidine 1/Thy1 1 cells (mean 4.7 6 0.09
with 48-hr biopsies). This progressive migration of MCsper glomerulus) that clustered close to the glomerular
toward the glomerular periphery occurred at an averagehilus. The glomerular peripheries, in contrast, were rela-
rate of 6 to 15 (mean 11.1) mm per day. There was notively devoid of Thy1-positive cells, consistent with prior
difference, however, in migratory distance attained bystudies [7]. A small number of 3[H] thymidine 1/Thy1 2
MCs from rats receiving anti-bFGF antibodies as com-cells (2 to 10) were apparent in many glomeruli (Fig.
4B). In prior studies, these cells were found to stain pared with rats receiving control IgG (69.9 6 6.0 mm vs.
positively for the monocyte/macrophage marker ED-1 72.9 6 5.2 mm from the hilus, P 5 0.25). Similar results
or the endothelial cell marker RECA-1 by double immu- were obtained when migratory distance was corrected
nolabeling [7]. for glomerular diameter (data not shown). These diver-
Sacrificial biopsies obtained at 96 hours showed an gent effects of anti-bFGF antibody on MC proliferation
exuberant mesangial proliferative response in which many and MC migration are summarized in Table 1.
glomeruli took on a lobular appearance (Fig. 3B). Ninety-
six hour autoradiographs (Fig. 4 C, D) revealed a marked
DISCUSSIONincrease in the number of 3[H]-thymidine 1/Thy1 1 cells
Mesangial injury is a feature of many human renalin all rats (11.9 6 4.2 vs. 4.7 6 0.9 at 48 hr, P , 0.0001)
diseases [18]. In both human disease and animal models,However, at 96 hours, biopsies from rats receiving neutral-
the MC responds to injury with a well-characterized pat-izing anti-bFGF antibodies had significantly fewer radiola-
beled MCs than rats receiving control IgG (8.7 6 1.9 vs. tern of cell proliferation, matrix expansion, and pheno-
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Fig. 4. Autoradiographs of biopsies obtained at 48 hours (A and B) and 96 hours (C and D) following injection of antithymocyte sera (3630).
Mesangial cells (MCs) are identified by positive staining for the surface antigen Thy1 (OX-7, dark gray). Tritium uptake is indicated by the
presence of black nuclear grains. (A) At 48 hours, radiolabeled mesangial cells (3[H]-thymidine 1/Thy1 1), indicated by arrows, are clustered
close to the hilus. (B) Strongly labeled MCs can be seen emanating from the hilus. A number of radiolabeled cells staining negatively for Thy1
can be seen scattered throughout the glomerulus (arrows). In prior studies, these were shown to stain positively for ED-1 (monocyte-macrophage)
or RECA-1 (endothelial cell) markers. (C and D) Ninety-six–hour biopsies from (C) a rat receiving neutralizing anti-bFGF antibodies and (D) a
rat receiving control IgG. Biopsies from rats receiving anti-bFGF had significantly fewer radiolabeled MCs at 96 hours, but the mean distance of
these cells from the hilus was similar in the two groups (Table 1).
typic alterations [9, 19]. More recently, we have been ing anti-bFGF antibodies to rats with Thy1 nephritis.
We found that proliferating MCs of rats receiving controlinterested in the processes governing glomerular repair
following immunologic injury [3–7]. Fundamental to the IgG underwent almost two cell divisions between 48 and
96 hours of disease. In contrast, MCs of rats receivingrestoration of glomerular architecture after experimental
mesangiolysis is the process of cell migration, in which neutralizing anti-bFGF antibodies divided only once,
yielding a 40% reduction in overall mesangial cellularity.mesangial progenitor cells taking origin in the extraglo-
merular mesangium migrate into the glomerular periph- It has been proposed that four criteria modeled on
Koch’s postulates must be met in order to demonstrateery. By a combined process of proliferation and migra-
tion, these cells have the potential to repopulate the a fundamental role for a growth factor in glomerular
disease [20, 21]. To this end, bFGF stimulates MC prolif-entire injured mesangium [7].
To explore the role of bFGF in the processes of MC eration in vitro [12]. bFGF is expressed within MCs dur-
ing the proliferative phase of the Thy1 model [13], andproliferation and migration, we administered neutraliz-
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Table 1. Effect of neutralizing anti-basic fibroblast growth factor virtually absent MC migration in response to bFGF at
(bFGF) antibodies on mesangial cell (MC)
a range of concentrations.proliferation and migration
In this study, in vivo MC migration was measured
# Proliferating Distance from by pulse-labeling proliferating MCs with 3[H]-thymidineMC/glom hilus lm
and tracking their course into the glomerulus by serial
48 Hour baseline 4.7 60.9 49.264.1
biopsy. As such, this assay will not measure the migration96 Hour F/U
Control IgG 14.7 63.5a 72.965.2b patterns of nonproliferating MCs. However, previous
Anti-bFGF 8.761.9 69.666.0 studies in this model [7] have shown that following mes-
a P 5 0.0001 vs. anti-bFGF treated rats angiolysis, essentially the entire mesangial repopulation
b P 5 NS
could be attributed to a process of serial MC replication.
Therefore, we believe that the assay used in this study
accounts for the majority of the MC migration occurring
in this model. Although we cannot exclude the possibilityadministration of bFGF to rats following subnephrito-
genic injury elicits MC proliferation [22]. Our current that migration occurred prior to initial labeling, this
should not alter the results observed, as antibody todata demonstrating that blocking bFGF in vivo inhibits
MC proliferation satisfy the fourth criteria, and strongly bFGF or control IgG was not given until after the base-
line (postlabeling) biopsy was obtained.implicate bFGF as an important mediator of MC prolif-
eration. In culture, bFGF has been shown to mediate the mi-
gration of a variety of cell lines, including endothelialRecently, Floege et al showed that administering rats
anti-bFGF or bFGF-blocking peptides prior to or shortly cells, fibroblasts, and glia [11]. bFGF is a potent SMC
mitogen [29], but its effects on SMC migration are lessafter (up to 8 hr) an injection of ATS mitigated the
degree of mesangiolysis and blocked glomerular mi- clear. In a rat model of carotid injury, daily administra-
tion of neutralizing anti-bFGF antibodies resulted in ancroaneurysm formation [23]. This early antibody treat-
ment resulted in a reduction in MC proliferation and 80% reduction in SMC migration from media to intima
[14]. However, bFGF does not appear to increase SMCmatrix production at day 4 of disease. The mechanism
underlying this reduction in proliferation was thought migration in culture [30]. Given the analogy of the acti-
vated MC to a SMC [31], it is not surprising that theto be a diminution in bFGF-induced cytotoxic injury,
perhaps a consequence of diminished glomerular nitric predominant effect of neutralizing antibody was a reduc-
tion in MC proliferation. In addition, our results areoxide production [23, 24]. In this study, we chose to
administer anti-bFGF starting at 48 hours following dis- consistent with previous studies showing that administra-
tion of neutralizing anti-bFGF antibodies to rats withease induction in order to minimize any effects of the
antibody on early cytotoxicity. Our observations of di- Thy1 nephritis did not effect expression of the migratory
proteins moesin and radixin [32].minished MC proliferation in rats receiving anti-bFGF
on days 2 and 3 of disease therefore more likely reflect A number of possibilities may explain this differential
effect of bFGF on MC functions. The stimulatory effectdirect inhibition of the mitogenic effects of bFGF.
Basic FGF is synthesized without a signal sequence of bFGF on the migration of certain cell types may in
part be mediated by its ability to up-regulate cellularand therefore lacks the structural features required for
conventional protein secretion [25]. Although the exact production of both plasminogen activator [28] and tissue
collagenases [33]. In this regard, it is interesting that a six-mode of cellular release of bFGF is unclear, it is thought
to be liberated following cellular injury [25], perhaps amino acid deletion in bFGF can dissociate its mitogenic
activity from its plasminogen activator-inducing capacitythrough plasma membrane disruptions [26]. There is evi-
dence, however, that bFGF can be released by viable [34]. Furthermore, in fetal bovine aortic endothelial cells,
the mitogenic signaling pathway has been found to becells and that it can stimulate cellular activities in an
autocrine fashion [27, 28]. In our study, the administra- mediated through protein kinase C, in contrast to the
plasminogen activator pathway, which appears to requiretion of blocking antibody after the mesangiolytic phase
had an inhibitory effect on proliferation, suggesting on- an intracellular calcium influx [35]. These findings sug-
gest that the effects of bFGF may be mediated throughgoing release of bFGF by viable MCs, or perhaps by
infiltrating macrophages or platelets. distinct signaling pathways, perhaps regulated at the re-
ceptor level. The expression of FGF receptors, a diverseIn contrast to the marked effect of anti-bFGF antibod-
ies on MC proliferation, we found no effects of blocking family consisting of numerous receptor isoforms, has
been found to be highly tissue specific [36]. The distribu-antibodies on the mean distance of radiolabeled MC
from the hilus on day 4 of disease or in the migratory tion of four high-affinity receptors (FGFR1 through
FGFR4) in the rat glomerulus has been investigated us-rate of these cells. Thus, neutralizing antibodies did not
appear to influence the process of MC migration. These ing immunofluorescence staining [37]. Although all four
receptor subtypes could be detected, the mesangiumresults were corroborated by our in vitro data showing
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stained most intensely for FGFR3, whereas the capillary Whether bFGF modulates mesangial events via such dif-
ferential signaling pathways is not known.loop stained predominantly for FGFR4 [37]. Although
What, then, are the cytokines likely to be involved inthe physiological distinctions of the FGF receptors have
MC migration? PDGF is one such protein. PDGF is anot been elucidated, it is tempting to hypothesize that
potent chemoattractant for a variety of cell lines [47]these different FGF receptor isoforms may mediate dif-
and reproducibly stimulates MC migration in vitro [48].ferential effects of the fibroblast growth factors within
In the Thy1 model, PDGF up-regulates the mesangialthe kidney.
expression of the migratory proteins moesin and radixinMigration requires mobilization of the cytoskeleton,
[32], suggesting an intimate link to the process of migra-whereas proliferation relies on nuclear transcription fac-
tion. Another protein likely to be important in MC mi-tors and the initiation of DNA synthesis. Although many
gration is thrombospondin (TSP) [49]. TSP is a highgrowth factors have the potential to act as both mitogens
molecular weight multifunctional glycoprotein initiallyand chemoattractants [38, 39], the molecular mechanisms
detected in platelet a-granules. TSP is widely expressedrequired to stimulate proliferation versus migration are
(fibroblasts, endothelial cells, SMCs, MCs) and mediatesnot well defined. Recent studies suggest that these pro-
a variety of diverse functions, including cell adhesion,cesses are mediated by distinct intracellular signaling
migration, proliferation, and angiogenesis [49]. Follow-pathways [40–42]. Using MCs in culture, Choudhury et
ing mesangiolytic injury in the Thy1 model, MC expres-al showed that complete inhibition of mitogen-activated
sion of TSP tightly correlates with MC proliferation [50].protein kinase (MAPK) by the inhibitor MEK (098059)
In culture, TSP stimulates MC adhesion and migrationreduced MC chemotaxis in response to PDGF by only
in a dose-dependent manner [51] and may very well41%, suggesting that MC migration is regulated by addi-
contribute to MC migration in vivo. Other factors likelytional signaling pathways [41]. In addition, Nelson et al
to influence in vivo MC migration include componentsshowed that PDGF-induced migration and proliferation
of the extracellular matrix [52] and the platelet releasateof SMCs are mediated by a temporal activation of the
fibronectin [53]. Further studies are needed to clarifysame MAPK system [43]. Early activation (15 min) was
the particular cytokine profile and extracellular milieurequired to induce cell migration, whereas later activa-
required for effective MC migration.tion (1 to 4 hr) was necessary to induce proliferation,
In summary, the role of bFGF appears to be that ofsuggesting that second-messenger proteins distal to the
a mitogen, rather than a migratory factor in glomerularMAPK pathway mediate these distinct cellular events
disease. bFGF appears to play an important role in the[43]. Although bFGF induced a similar MAPK activation
proliferative process necessary for restoration of mesan-pattern in cultured SMCs [44], it did not elicit SMC
gial architecture following injury. In contrast, bFGF ismigration [30]. These studies suggest that activation of
not a significant MC chemoattractant in vitro and is un-signaling pathways, both independent of and distal to
likely to contribute to the process of MC migration inthe MAPK system, is necessary to induce migration in
vivo. Importantly, these studies provide the first demon-response to both bFGF and PDGF. One such signaling
stration, to our knowledge, that factors mediating prolif-pathway may involve the phosphorylation of focal adhe-
eration can be dissociated from those mediating migra-sion kinase (FAK). FAK is an nonreceptor/intracellular
tion in renal injury. This may have implications for ourprotein tyrosine kinase that localizes to focal adhesion
understanding of the MC repopulation that occurs incontacts [45]. By modulating integrin-mediated binding
development and disease.to extracellular matrix, FAK is thought to play a key
role in cell adhesion and migration [45]. Jiang et al
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